• About Us
    • Our Company
    • Management & Board
    • Who We Help
  • Our Approach
    • Toll-Like Receptor Activation
    • Publications & Presentations
  • Areas of Focus
    • Immuno-Oncology
    • Pipeline & Programs
  • Investor Relations
  • Join Us
×

A Phase 1-2 study to evaluate the safety and efficacy of intratumoral injection of the TLR9 agonist tilsotolimod in combination with ipilimumab in PD-1 inhibitor refractory MM

© 2022 Idera. All rights reserved.

  • Contact Us
  • Terms of Use
  • Privacy Policy